A mutant of Escherichia coli (indoR) has been isolated which is defective in synthesis of the membrane-derived oligosaccharides (MDO) normally found in the periplasmic space. In media of high osmotic pressure this defect is suppressed and MDO levels approaching those of the wild type are produced. The mdoR mutant also fails to accumulate glycogen; however, genetic analysis showed that mdoR was not cotransducible with the known glg (glycogen) locus. A further relationship between MDO and glycogen metabolism was suggested by two observations that (i) certain glg mutants affect MDO accumulation and (ii) elevated osmotic pressure inhibits glycogen accumulation, in both wild-type and mdoR cells.
The membrane-derived oligosaccharides (MDO) of Escherichia coli were discovered by van Golde et al. (16) and subsequently characterized by Kennedy's laboratory (7, 9) .
The MDO contain 8 to 10 glucose units joined by p1-2 and P1-6 linkages into a branched structure (7) . Attached to the sugars are substituents such as phosphorylglycerol and phosphorylethanolamine derived from the head groups of the membrane phospholipids (9) . The MDO are found in the periplasmic space (15) and are thought to be involved in the osmoregulation of this cellular compartment (8) . I recently discovered that E. coli strain DC2, a mutant originally selected for hypersensitivity to antibiotics (13) , had a fortuitious defect in MDO production. Further investigation showed the mdoR lesion to be quite distinct genetically from the antibiotic hypersensitivity (abs) mutation. The mdoR mutation is presumably regulatory in nature since expression of MDO synthesis depends strongly on medium osmotic pressure in such strains. In addition, mdoR affects the accumulation of another carbohydrate, glycogen.
MATERIALS AND METHODS
Bacterial strains and media. All strains used are Escherichia coli K-12 and are listed in Table 1 . The isolation and characterization of DC2 have been previously described (5, 13) . Rich broth contained, per liter, 10 g of tryptone, 5 g of NaCl, and 1 g of yeast extract. Minimal medium was M9 (10) , and carbon sources were added to 0.4% (wt/vol). Growth of strains for routine extraction and assay of MDO was in M9 salts diluted by two, supplemented with potassium lactate (0.4%), casein amino acids (0.1%), and methionine (50 ,ug/ml).
Some experiments were also performed with the Tris-based medium of Kennedy (8) .
Extraction and assay of MDO. After harvesting by centrifugation, cell pellets were washed in 0.85% saline and then extracted in 50% ethanol (5 ml per 100 ml of original culture), as described by van Golde et al. (16) . MDO extracts were then assayed for sugars by either the phenol-sulfuric acid (11) or the anthrone (11) assay. Amino groups were assayed by the trinitrobenzene sulfonate method (6) and phosphate was assayed by the molybdate reagent (1) .
In some experiments the MDO was purified on a Bio-Gel P10 column as described by van Golde et al. (16) , using 10 mM Tris-hydrochloride (pH 7.4) containing 20 mM NaCl and 5% n-propanol as elution buffer.
RESULTS
Mutant DC2 was originally isolated as an antibiotic-hypersensitive (abs) mutant derived from the parental strain UB1005, as described previously (13) . Further investigation of this strain indicated a lack of the MDO described by Kennedy's laboratory (16) .
Absence of MDO in DC2. Cultures of UB1005 and DC2 grown on lactate as carbon source were labeled with ["4C]glucose, and the MDO fraction was analyzed on a Bio-Gel P10 column as described in Materials and Methods. Two peaks of carbohydrate-containing material were seen with UB1005 (Fig. 1) . The minor peak was associated with most of the detectable amino and phosphate groups (Fig. 2) . In contrast, DC2 showed very little carbohydrate-containing material in the equivalent fractions, whether assayed by ['4C]glucose incorporation (Fig. 1) or chemical assay using the anthrone reagent (Fig. 2) . The amine and phosphate content of the minor MDO peak of DC2 was reduced about 50% relative to the wild type, whereas the sugar content of these fractions was reduced by over 90% (Fig. 2) . (The phosphate content of the MDO fractions paralleled that of the amine content, but has been omitted from the figures for the sake of clarity.)
This suggested that a noncarbohydrate substance containing phosphate and amine groups was running together with the minor MDO peak. To check both this and the correct identification of the MDO peaks, we analyzed strain DF40, a pgi mutant. It has been shown previously that pgi strains cannot synthesize glucose de novo and can therefore make MDO only when provided with exogenous glucose (14) . We grew DF40 in the presence or absence of glucose and analyzed the MDO as before. In the absence of glucose no MDO was detectable with carbohydrate assays, yet amineand phosphate-containing material was present where the minor MDO peak would run (Fig. 3) . This second peak presumably contains metabolic intermediates, nucleotides, etc.
Distinction of the MDO defect from the antibiotic hypersensitivity lesion of DC2. The properties and map location of the abs (antibiotic hypersensitivity) mutation of DC2 have been described before (5 ductants, DC107 and DC108, were examined for MDO production, and both showed MDO levels identical tothose of DC2 (Table 2 ). Several spontaneous revertants of DC2, selected for recovery of wild-type resistance to chloramphenicol or methicillin, were also assayed ( Table 3 ). All of these resembled DC2 in having very little MDO. The converse experiment was also performed. The abs+ mutation was transduced into H882 (purA), using P1 grown on DC2, by selecting for the neighboring purA marker. Both DC135 (purA+ abs+) and DC136 (purA+ abs-2) showed identical wild-type levels of MDO (data not shown). Thus, the abs mutation of DC2 is not responsible for the lack of MDO in this strain. As expected, when strain DF40 (pgi) was grown in the absence of glucose, and therefore could not make MDO, it showed no increase in susceptibility to antibiotics such as chloramphenicol (data not shown). Thus, the abs and mdoR defects are both genetically and phenotypically distinct.
Another indication that abs and mdoR are distinct comes from the disparate effect of deoxy sugars on MDO synthesis and antibiotic hypersensitivity. As reported previously, 2-deoxyglucose and other deoxy sugars suppress the antibiotic hypersensitivity of DC2 (5). However, when UB1005 and DC2 were grown in the presence of 2-deoxyglucose both strains showed the very low level of MDO observed when strain DF40, a phosphoglucose isomerase mutant, was grown in the absence of exogenous glucose (Table 4 ). This represents a relative drop of about 50% for DC2 and 5-to 10-fold for UB1005. Thus, deoxy sugars strongly. inhibit MDO synthesis, including the residual synthesis found in DC2, and therefore would accentuate rather than suppress any properties due to a defect in MDO production. MDO of pgi mutant. Strain DF40 pgi was grown on lactate-Casamino Acids in minimal medium with or without glucose (0.2%) and was analyzed for MDO-associated carbohydrate and amino groups, exactly as described in the legend to Fig. 2 . The phosphate assays have again been omitted for the sake of clarity.
presence of 3% NaCl, suggesting that a lack of MDO might indeed prevent growth in media of high osmotic pressure. This paradox was resolved by assaying both mdoR mutants and wild-type strains under conditions of varying osmotic pressure. The mdoR defect is partially supprgosed by increasing the osmotic pressure of the culture medhim (Fig. 4) . In both DC108 abs+ mdoR (Fig. 4) and DC2 abs-2 mdoR (data not shown) the MDO content increases in media of elevated osmotic pressure, approaching that of the wild type in medium supplemented with 3% NaCl. The MDO content of all strains, both wild type and mutants, increases with increasing osmotic pressure (Fig. 4) . Thus, the mdoR mutation of DC2 and DC108 would appear to be regulatory in nature, aifecting MDO production most markedly in media of low osmolarity.
Mutants in carbohydrate metabolism. Lack of MDO has been observed in inutants unable to synthesize glucose, such as pgi (14) . My results with DF1311 (pgi pgl) and DF40 (pgi) confirm this ( Fig. 3; Table 4 ). I also found that DF2001 (zwfA) and PGM1 (pgm) produced very little MDO (Table 4) .
However, strain DC2 (mdoR) does not show the phenotype characteristic of any of these mutants in sugar metabolism. Furthermore, DC2 fails to make MDO even when provided with glucose ( Fig. 1) , whereas mutants in glucose synthesis such as pgi recover the ability to make MDO under such conditions (Fig. 3) . Thus the mdo lesion of DC2 is not merely a defect in central carbohydrate metabolism. Relationship between glycogen and MDO. In stationary phase, glucose is converted to glycogen (4) which, like MDO, is located in the cell envelope (12) . Staining for glycogen accumulation with I2 in KI (4) indicated that DC2, DC108, and the various other abs+ revertants and transductants of DC2 all failed to synthesize significant amounts of glycogen. The previously characterized (4) glycogen-defective mutant LCB498 (glgA) and the overproducer LCB618 (glgC) were therefore examined for MDO. Lack of glycogen synthetase (glgA) did not affect MDO levels (Table 5) . However, overproduction of ADP-glucose pyrophosphorylase, the enzyme responsible for the synthesis of the glycogen precursor ADP-glucose, by the glgC mutant LCB618 did result in increased levels of MDO (Table 5 ). The glgA and glgC mutations were transduced into UB1005, DC2, and DC108, using an insertion of TnJO into the nearby malT locus as the selective marker. MDO assays were performed on extracts of strains bearing all possible combinations of glg+, gigA, and glgC with mdo+ and mdoR ( Table 5 ). The results confirmed that a lesion in glgA had no effect on MDO levels, whereas the presence of a glgC mutation increased MDO production severalfold, in both the UB1005 wild type and the DC2 mdoR backgrounds. The observations suggested that MDO and glycogen might share a common precursor and that the osmolarity of the medium might regulate the relative flux to MDO and glycogen as alternative end products. If this were so, one might expect that glycogen synthesis would be greatly reduced as the osmotic pressure increased. In support of this idea, when 2 or 3% NaCl was added to the low-nitrogen minimal medium used to stimulate glycogen production, almost no detectable glycogen was formed by either the wild type or mdo mutants.
The mdoR gene is not at the glg locus. Since mdoR affects glycogen synthesis it seemed possible that it might map in the glgABC operon at 75 min (2) . Therefore, cotransductions Revertants of mdoR. In the original characterization of the abs mutantp it was stated that DC2 is not temperature sensitive (5) . Although this is true on most media, I later found that both DC2 (abs-2 mdoR) and DC108 (abs; mdoR) were unable to grow at 42°C on M9 minimal medium. Another difference between the wild type and the mdoR mutants was in their resistance to borate. Although absolute levels of resistance to borate varied appreciably with the Revertants of DC2 were selected by growth on minimal medium at 42°C or by resistance to borate. Both types of revertant behaved identically; all grew at 42°C, showed the borate resistance characteristic of the wild type, and were positive for glycogen production. Levels of MDO in the revertants varied widely, some having scarcely more than DC2 and others having wild-type levels (Table 6 ). Several revertants showing wild-type levels of MDO were examined in media of both low and high osmolarity. These revertants showed the increase in MDO accumulation with increasing osmolarity common to both the wild type and the mdoR mnutants.
DISCUSSION
Until recently the only strains of E. coli known to be defective in the production of MDO were mutants of central carbohydrate metabolism (e.g., pgi) which are unable to syn'thesize glucose (14) . When provided with exogehous glucose such strains regain the ability to make MDO. The mdoR mutation found in strain DC2 is different in two respects. First, exogenous glucose does not allow MDO synthesis; hence, DC2 is not merely a mutant defective in gluconeogenesis. Second, the mdoR mutation of DC2 is osmoremedial. In media of high osmolarity synthesis of MDO resumes, suggesting that the lesion in DC2 is in a regulatory gene. Bohin on September 30, 2017 by guest http://jb.asm.org/ Downloaded from cose is presumably the major in vivo precursor of MDO at low osmolarity, the nature of the precursor for MDO at elevated osmotic pressures remains to be clarified. We are presently examining further the effects of varying the levels of the UDP-glucose and ADP-glucose synthetases upon MDO accumulation.
The effect of mdoR on glycogen also suggested the possibility that the MDO deficiency in DC2 was merely the result of a regulatory mutation at the glg operon. However, transduction of a wild-type glg region into DC2 indicated that the mdoR mutation is not in or near the glg operon. In high osmotic pressure the amount of MDO increased markedly in both wild type and mutants. In contrast, in the presence of high salt concentrations, little or no glycogen accumulation was visible even in the wild type. This suggests that mdoR may affect the supply of a common precursor to both glycogen and MDO. Not only NDP-glucose derivatives but also glucose-i-phosphate might be involved.
As the osmolarity of the medium increases, MDO accumulates and glycogen accumulation is correspondingly curtailed.
My observation that the content of MDO increases with increasing osmolarity is apparently in disagreement with the results of Kennedy (8) . In an attempt to resolve this conflict I obtained strain BB26-36, used by Kennedy in his study of the osmoregulation of MDO synthesis. Both BB26-36 and UB1005 were grown in the Tris-based medium used by Kennedy (8) , and we found that whereas the MDO content of BB26-36 decreased with increasing osmotic pressure, as described by Kennedy, the MDO content of UB1005 increased (Rod and Clark, unpublished data). Thus, the apparent discrepancy between Kennedy's work and that described here is due to differences in response to elevated osmolarity among different E. coli strains. We are presently examining several strains of E. coli ancestral to both Kennedy's and our own which were kindly provided by Barbara Bachmann of the E. coli Genetic Stock Center. Preliminary results suggest considerable strain variation in the osmotic regulation of MDO synthesis (Rod and Clark, unpublished data).
According to anthrone assays performed on crude 50% ethanol extracts, strain DC2 has approximately 30% of the MDO content of its parent (Table 2) . However, purification of [14C]glucose-labeled MDO on Bio-Gel P10 (Fig. 1) indicates that DC2 contains almost no MDO. Data for the pgi mutants are similar. Most crude 50% ethanol extracts of all strains contain an appreciable amount of anthrone-positive material, probably metabolic intermediates, which is not MDO. For routine assay of MDO levels in transductants, revertants, etc., this interfering material was included in the MDO content without correction. Despite this, the mdoR phenotype was never in doubt.
Another source of experimental variation in measuring the content is due to the alteration of MDO levels with growth phase. MDO increases to a maximum in early stationary phase. If incubation is continued into far stationary phase (i.e.,10 to 20 h after growth stops), the MDO gradually disappear (data not shown). Values of MDO vary from 2 to 4 ,ug/109 cells for DC2 and from 7 to 14 ,ug/109 cells for UB1005, depending on whether cultures are harvested in late exponential or early stationary phase. Replicate cultures, grown to identical cell densities in the same medium, vary by approximately 20% in their MDO content in our hands. There are also differences in MDO production in different media, distinct from those alterations due to changes in osmolarity. Further experiments are in progress to characterize these variations more fully.
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